Resource utilization before and during infliximab therapy in patients with inflammatory bowel disease

References

• Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis 2006;12:s3-s9
   PubMed Web of Science ®Google Scholar
• DiPiro JT, Schade RR. Inflammatory bowel disease. In: DiPiro JT, Talbert RL, Yee GC, et al., eds. Pharmacotherapy: a pathophysiologic approach, 6th edn. New York: McGraw-Hill Companies, Inc, 2005. p 1007-21
   Google Scholar
• Card T, Hubbard R, Logan RF. Mortality in inflammatory bowel disease: a population-based cohort study. Gastroenterology 2003;125:1583-90
   PubMed Web of Science ®Google Scholar
• Feagan BG, Vreeland MG, Larson LR, et al. Annual cost of care for Crohn’s disease: a payor perspective. Am J Gastroenterol 2000;95:1955-60
   PubMed Web of Science ®Google Scholar
• Pohl C, Hombach A, Kruis W. Chronic inflammatory bowel disease and cancer. Hepatogastroenterology 2000;47:57-70
   PubMedGoogle Scholar
• Roifman I, Sun YC, Fedwick JP, et al. Evidence of endothelial dysfunction in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2009;7:175-82
   PubMed Web of Science ®Google Scholar
• Graff LA, Walker JR, Clara I, et al. Stress coping, distress, and health perceptions in inflammatory bowel disease and community controls. Am J Gastroenterol 2009;104:2959-69
   PubMed Web of Science ®Google Scholar
• Drossman DA, Patrick DL, Mitchell CM, et al. Health-related quality of life in inflammatory bowel disease. Functional status and patient worries and concerns. Dig Dis Sci 1989;34:1379-86
   PubMed Web of Science ®Google Scholar
• Bernklev T, Jahnsen J, Henriksen M, et al. Relationship between sick leave, unemployment, disability, and health-related quality of life in patients with inflammatory bowel disease. Inflamm Bowel Dis 2006;12:402-12
   PubMed Web of Science ®Google Scholar
• Longobardi T, Jacobs P, Wu L, et al. Work losses related to inflammatory bowel disease in Canada: results from a National Population Health Survey. Am J Gastroenterol 2003;98:844-9
   PubMed Web of Science ®Google Scholar
• Longobardi T, Jacobs P, Bernstein CN. Work losses related to inflammatory bowel disease in the United States: results from the National Health Interview Survey. Am J Gastroenterol 2003;98:1064-72
   PubMed Web of Science ®Google Scholar
• Kornbluth A, Sachar DB; and the Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010;105:501-23
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Hanauer SB, Sandborn WJ; and the Practice Parameters Committee of the American College of Gastroenterology. Management of Crohn’s disease in adults. Am J Gastroenterol 2009;104:465-83
   PubMed Web of Science ®Google Scholar
• Frøslie KF, Jahnsen J, Moum BA, et al; and the IBSEN Group. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007;133:412-22
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Vermeire S, Van Assche G. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut 2007;56:453-5
   PubMed Web of Science ®Google Scholar
• Remicade [package insert]. Horsham, PA: Janssen Biotech, Inc., 2010
   Google Scholar
• Humira [package insert]. North Chicago, IL: Abbott Laboratories, 2009
   Google Scholar
• Cimzia [package insert]. Smyrna, GA: UCB, Inc., 2009
   Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR, et al; and the ACCENT I Study Group. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9
   PubMed Web of Science ®Google Scholar
• Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 2004;350:876-85
   PubMed Web of Science ®Google Scholar
• Sands BE, Blank MA, Patel K, et al. Long-term treatment of rectovaginal fistulas in Crohn’s disease: response to infliximab in the ACCENT II study. Clin Gastroenterol Hepatol 2004;2:912-20
   PubMed Web of Science ®Google Scholar
• Targan SR, Hanauer SB, van Deventer SJH, et al; for the Crohn’s Disease cA2 Study Group. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn’s disease. N Engl J Med 1997;337:1029-35
   PubMed Web of Science ®Google Scholar
• Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 1999;340:1398-405
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76
   PubMed Web of Science ®Google Scholar
• Hyams J, Crandall W, Kugathasan S, et al; and the REACH Study Group. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn’s disease in children. Gastroenterology 2007;132:263-73
   Web of Science ®Google Scholar
• Danese S. Mechanisms of action of infliximab in inflammatory bowel disease: an anti-inflammatory multitasker. Dig Liver Dis 2008;40(2 Suppl):S225-8
   PubMedGoogle Scholar
• Longobardi T, Jacobs P, Bernstein CN. Utilization of health care resources by individuals with inflammatory bowel disease in the United States: a profile of time since diagnosis. Am J Gastroenterol 2004;99:650-5
   PubMed Web of Science ®Google Scholar
• Longobardi T, Bernstein CN. Utilization of health-care resources by patients with IBD in Manitoba: a profile of time since diagnosis. Am J Gastroenterol 2007;102:1683-91
   PubMed Web of Science ®Google Scholar
• HCUPnet, Healthcare Cost and Utilization Project. Agency for Healthcare Research and Quality. Rockville, MD. Available at: http://hcupnet.ahrq.gov. Accessed March 1, 2010
   Google Scholar
• Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. Direct health care costs of Crohn’s disease and ulcerative colitis in US children and adults. Gastroenterology 2008;135:1907-13
   PubMed Web of Science ®Google Scholar
• 2010 Medicare Physician Fee Schedule Lookup. Centers for Medicare and Medicaid Services. Baltimore, MD. Available at: http://www.cms.hhs.gov/pfslookup. Accessed March 1, 2010
   Google Scholar
• Schnitzler F, Fidder H, Ferrante M, et al. Infliximab therapy for refractory Crohn's disease (CD) decreases the long-term need for bowel surgery. Gastroenterology 2008;134(1 Suppl):A134
   Google Scholar
• Schnitzler F, Fidder H, Ferrante M, et al. Maintenance Q8 therapy of Crohn's disease with infliximab is associated with endoscopic mucosal healing in the long-term. Gastroenterology 2008;134(1 Suppl):A133
   Google Scholar
• Rubenstein JH, Chong RY, Cohen RD. Infliximab decreases resource use among patients with Crohn’s disease. J Clin Gastroenterol 2002;35:151-6
   PubMed Web of Science ®Google Scholar
• Jewell DP, Satsangi J, Lobo A, et al. Infliximab use in Crohn's disease: impact on health care resources in the UK. Eur J Gastroenterol Hepatol 2005;17:1047-52
   PubMed Web of Science ®Google Scholar
• Wright R, Truelove SR. Serial rectal biopsy in ulcerative colitis during the course of a controlled therapeutic trial of various diets. Am J Dig Dis 1966;11:847-57
   PubMedGoogle Scholar
• Lichtenstein GR, Rutgeerts P. Importance of mucosal healing in ulcerative colitis. Inflamm Bowel Dis 2010;16:338-46
   PubMed Web of Science ®Google Scholar